Efficacy of P2Y₁₂ receptor inhibitors in myocardial infarction in individuals carrying different CYP2C19 genotypes living in the northern region of Russia

Aim. To evaluate the efficacy of P2Y₁₂ receptor inhibitors (clopidogrel and ticagrelor) in patients with myocardial infarction (MI) living in the northern region of Russia (Khanty-Mansi Autonomous Okrug — Yugra), depending on the carriage of various CYP2C19 allelic variants.

Material and methods. This prospective observational study included 218 patients with acute MI who underwent percutaneous coronary intervention (PCI). The patients also underwent determination of allelic variants of the CYP2C19 gene. Patient were divided into groups receiving clopidogrel (n=164, 75%) and ticagrelor (n=54, 25%). Using biostatistical analysis methods, a comparison of clinical and genetic characteristics was performed, as well as an assessment of the risk of ischemic events between the groups in the long-term (108 months, 9 years) post-infarction period.

Results. Reduced (*1/*2, *2/*2, *1/*3) and increased (*1/*17, *17/*17) metabolizer CYP2C19 genotypes, as well as severe comorbidity, are reliable independent predictors of composite outcome (cardiovascular death, recurrent acute coronary syndrome, coronary stent/bypass thrombosis, myocardial revascularization, acute ischemic cerebrovascular accident) during a long-term (9 years) follow-up. The advantages of ticagrelor over clopidogrel in terms of the effect on the incidence of ischemic events in the long-term period were established without a significant difference for bleeding both in the general cohort of patients and among carriers of CYP2C19 allelic variants (*1/*2, *2/*2, *1/*3) and (*1/*17,*17/*17) in patients with MI.

Conclusion. Ticagrelor is significantly more effective than clopidogrel in reducing the risk of ischemic events in the general cohort of patients, as well as in carriers of reduced (*1/*2, *2/*2, *1/*3) and increased (*1/*17, *17/*17) metabolizer CYP2C19 genotypes during 9-year follow-up after the index MI.

1. Castrichini M, Luzum JA, Pereira N. Pharmacogenetics of Antiplatelet Therapy. Annual Review of Pharmacology and Toxicology. 2023;20;63:211-29. doi:10.1146/annurev-pharmtox-051921-092701.

2. Sibbing D, Aradi D, Alexopoulos D, et al. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. Journal of American College of Cardiology: Cardiovascular Interventions. 2019;12(16):1521-37. doi:10.1016/j.jcin.2019.03.034.

3. Klyaritskaya IL, Rabotyagova Yu S. Detection of cypochrome P450 2C19 gene polymorphism to optimize therapy of acid-dependent diseases. Clinical Medicine. 2015; 93(1):46-50. (In Russ.)

4. Ellithi M, Baye J, Wilke RA. CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls. Pharmacogenomics. 2020;21(12):889-97. doi:10.2217/pgs-2020-0046.

5. Mirzaev KB, Zelenskaya EМ, Barbarash OL, et al. The frequency of CYP2C19 allelic variants in patients with acute coronary syndrome in Central, Eastern, Northern Siberia and Moscow region. Creative Cardiology. 2017;11(1):8-19. (In Russ.) doi:10.15275/kreatkard.2017.01.02.

6. Kantemirova BI, Orlova EA, Polunina OS, et al. Pharmacogenetic bases of individual sensitivity and personalized administration of antiplatelet therapy in different ethnic groups. Pharmacy & Pharmacology. 2020;8(6):392-404. (In Russ.) doi:10.19163/2307-9266-2020-8-6-392-404.

7. Nikolaev KY, Urvantseva IA, Batueva KYu, et al. Regional aspects of associations of the CYP2C19 gene polymorphism with coronary atherosclerosis in acute coronary syndrome. Russian Journal of Cardiology. 2018;(10):28-32. (In Russ.) doi:10.15829/1560-4071-2018-10-28-32.

8. Vorobyov AS, Lifshits GI, Zelenskaya EM, et al. Clinically significant CYP2C19 genotypes in patients with myocardial infarction in the northern region of Russia. Russian Journal of Cardiology. 2023;28(10):5533. (In Russ.) doi:10.15829/1560-4071-2023-5533.

9. Grazhdankin IO, Prokhorikhin AA, Baystrukov VI, et al. Impact of CYP2C19 gene polymorphisms on clinical outcomes in patients with myocardial infarction during 60 months of follow-up. Patologiya krovoobrashcheniya i kardiokhirurgiya. 2023;27(4):64-76. (In Russ.) doi:10.21688/1681-3472-2023-4-64-76.

10. Lyu SQ, Yang YM, Zhu J, et al. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Platelets. 2020;31(8):971-80. doi:10.1080/09537104.2020.1780205.

11. Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy: A Meta-Analysis. Journal of American College of Cardiology. Cardiovascular Interventions. 2021;14(7):739-50. doi:10.1016/j.jcin.2021.01.024.

12. Claassens D, Vos G, Bergmeijer T, et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. New England Journal of Medicine. 2019;381(17):1621-31. doi:10.1056/NEJMoa1907096.

13. Pereira NL, Farkouh ME, So D, et al. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. Journal of American Medical Association. 2020;324(8):761-71. doi:10.1001/jama.2020.12443.

14. Bertrand-Thiébault C, Berrahmoune H, Thompson A, et al. Genetic Polymorphism of CYP2C19 gene in the Stanislas cohort. A link with inflammation. Annals of Human Genetics. 2008;72 (Pt 2):178-83. doi:10.1111/j.1469-1809.2007.00417.x.

15. Tekeste R, Garza G, Han S, et al. Ticagrelor is more effective than clopidogrel in carrier of nonfunctional CYP2C19 allele who has diabetes and acute coronary syndrome — case report and literature review. AIMS Molecular Science. 2022;9(2):66-78. doi:10.3934/molsci.2022004.